Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban concentration, anti-factor Xa activity and prognosis in DVT
ChiCTR-OPC-17011716Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in deep vein thrombosis (DVT), sponsored by Peking Union Medical College Hospital. Primary endpoints: Rivaroxaban blood concentration and Anti-factor Xa activity. Started Jul 2017; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR-OPC-17011716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011716.